276 related articles for article (PubMed ID: 26926466)
1. Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research.
Jiménez-Valerio G; Casanovas O
Curr Drug Targets; 2016; 17(15):1728-1734. PubMed ID: 26926466
[TBL] [Abstract][Full Text] [Related]
2. Resistance to antiangiogenic therapies.
Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic strategies and agents in clinical trials.
Rosen L
Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
[TBL] [Abstract][Full Text] [Related]
4. The possible role of chemotherapy in antiangiogenic drug resistance.
Bocci G; Loupakis F
Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy.
Albo D; Wang TN; Tuszynski GP
Curr Pharm Des; 2004; 10(1):27-37. PubMed ID: 14754403
[TBL] [Abstract][Full Text] [Related]
6. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
7. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.
Ebos JM; Lee CR; Kerbel RS
Clin Cancer Res; 2009 Aug; 15(16):5020-5. PubMed ID: 19671869
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and future directions for angiogenesis-based cancer therapies.
Scappaticci FA
J Clin Oncol; 2002 Sep; 20(18):3906-27. PubMed ID: 12228212
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
10. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
Gagne P; Akalu A; Brooks PC
Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
[TBL] [Abstract][Full Text] [Related]
11. The great escape; the hallmarks of resistance to antiangiogenic therapy.
van Beijnum JR; Nowak-Sliwinska P; Huijbers EJ; Thijssen VL; Griffioen AW
Pharmacol Rev; 2015; 67(2):441-61. PubMed ID: 25769965
[TBL] [Abstract][Full Text] [Related]
12. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
14. The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.
Mastri M; Rosario S; Tracz A; Frink RE; Brekken RA; Ebos JM
Curr Drug Targets; 2016; 17(15):1747-1754. PubMed ID: 26648063
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic inhibitors: a new therapeutic strategy in oncology.
Gasparini G; Longo R; Toi M; Ferrara N
Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
[TBL] [Abstract][Full Text] [Related]
16. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic agents and targets: A perspective.
Teicher BA
Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
[TBL] [Abstract][Full Text] [Related]
18. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and Metabolism: Entwined for Therapy Resistance.
Jiménez-Valerio G; Casanovas O
Trends Cancer; 2017 Jan; 3(1):10-18. PubMed ID: 28718423
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of novel antiangiogenic therapies.
Scappaticci FA
Expert Opin Investig Drugs; 2003 Jun; 12(6):923-32. PubMed ID: 12783597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]